Variable2 | Gln/Arg/HMB (n = 30) | Placebo (n = 30) | P3 | P-adjusted 14 |
---|---|---|---|---|
AST (IU/L) | ||||
Baseline | 22.16 ± 4.86 | 20.53 ± 5.00 | 0.209 | 0.246 |
End of the study | 40.00 ± 14.65 | 27.83 ± 13.54 | 0.002 | 0.008 |
Changes | 17.83 ± 12.45 | 7.30 ± 13.62 | 0.003 | 0.011 |
P5 | <0.001 | 0.006 | ||
ALT (IU/L) | ||||
Baseline | 20.0 (8.0) | 21.0 (9.25) | 0.450* | 0.960¥ |
End of the study | 16.0 (13.0) | 19.50 (20.50) | 0.278* | 0.070¥ |
Changes | 0.0 (12.5) | -1.50 (20.50) | 0.462* | 0.145¥ |
P5 | 0.123* | 0.802* | ||
Total bilirubin (mg/dL) | ||||
Baseline | 1.20 (1.275) | 0.50 (0.50) | <0.001* | <0.001¥ |
End of the study | 0.80 (0.55) | 1.00 (0.50) | 0.198* | 0.061¥ |
Changes | −0.40 (0.92) | 0.42 (0.60) | <0.001* | <0.001¥ |
P5 | 0.002* | 0.001* | ||
Direct bilirubin (mg/dL) | ||||
Baseline | 0.50 (0.10) | 0.50 (0.12) | 0.065* | 0.024¥ |
End of the study | 0.50 (0.20) | 0.40 (0.22) | 0.004* | 0.165¥ |
Changes | 0.0 (0.30) | 0.0 (0.31) | 0.451* | 0.965¥ |
P5 | 0.301* | 0.075* | ||
Indirect bilirubin (mg/dL) | ||||
Baseline | 0.70 (0.50) | 0.50 (0.22) | 0.003* | 0.001¥ |
End of the study | 0.60 (0.60) | 0.65 (0.50) | 0.964* | 0.257¥ |
Changes | −0.10 (0.40) | 0.20 (0.50) | 0.008* | 0.012¥ |
P5 | 0.214* | 0.007* |